DEV infects and lyses Pseudomonas aeruginosa bacteria, an opportunistic pathogen in cystic fibrosis and other diseases. DEV is part of an experimental phage cocktail developed to eradicate P.

With the rapid development of antibiotics in the 1930s, phage therapy—using viruses known as bacteriophages or phages to ...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first 'Phagogram Day'This event, organized in ...

But in this case, a phage molecule is secreted by the bacteria themselves, and it has a symbiotic relationship with Pseudomonas aeruginosa. In fact, it forms these liquid crystalline droplets ...

DEV infects and lyses Pseudomonas aeruginosa bacteria, an opportunistic pathogen in cystic fibrosis and other diseases. DEV ...

a top candidate for inclusion into Armata's multi-phage anti-Pseudomonas clinical products The publication, titled, "Cryo-EM analysis of Pseudomonas phage Pa193 structural components," describes ...

DEV infects and lyses Pseudomonas aeruginosa bacteria, an opportunistic pathogen in cystic fibrosis and other diseases. DEV ...

a top candidate for inclusion into Armata's multi-phage anti-Pseudomonas clinical products LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP ...

Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.